Condition: High-risk Muscle Invasive Urothelial Carcinoma · Sponsor: AstraZeneca
Purpose: to assess efficacy and safety of Dato-DXd + rilvegostomig as adjuvant therapy versus SoC in MIUC participants with high-risk residual disease after radical resection. Study details: Duration: \~78 months (6.5 years) from FSI to last subject visit Treatment length: up to \~12 months, depending on randomized arm Visit frequency: every 3 weeks in Arms 1 and 2; every 2-4 weeks per SoC in Arm 3
This description comes directly from the study's public registry record.
AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com
Always discuss trial participation with your own doctor first.
| Research Site | Hot Springs, Arkansas, United States | Not Yet Recruiting |
| Research Site | Little Rock, Arkansas, United States | Not Yet Recruiting |
| Research Site | Little Rock, Arkansas, United States | Not Yet Recruiting |
| Research Site | San Francisco, California, United States | Not Yet Recruiting |
| Research Site | Chicago, Illinois, United States | Withdrawn |
| Research Site | Boston, Massachusetts, United States | Not Yet Recruiting |
| Research Site | Kansas City, Missouri, United States | Not Yet Recruiting |
| Research Site | Lincoln, Nebraska, United States | Not Yet Recruiting |
| Research Site | Omaha, Nebraska, United States | Not Yet Recruiting |
| Research Site | Albany, New York, United States | Not Yet Recruiting |
| Research Site | New York, New York, United States | Not Yet Recruiting |
| Research Site | Cleveland, Ohio, United States | Not Yet Recruiting |
+ 148 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07720284